Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,571.78 55.51 0.38%
TOPIX 1,175.44 2.07 0.18%
HANG SENG 22,760.24 64.23 0.28%

Vermillion Appoints Dr. Eric Varma to its Board of Directors



         Vermillion Appoints Dr. Eric Varma to its Board of Directors

PR Newswire

AUSTIN, Texas, Sept. 16, 2013

AUSTIN, Texas, Sept. 16, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, today announced the appointment of Eric Varma, M.D. to its board of
directors.

"As a partner at Oracle Investment Management, Vermillion's largest
shareholder, and a physician, Eric brings significant financial and commercial
experience in the life sciences to our board of directors," said Thomas
McLain, Vermillion's president and CEO. "His expertise will help guide the
company as it continues to focus on its novel, high-value diagnostic test,
OVA1® and improving the care for women with gynecological cancers."

Dr. Varma is currently a partner at Oracle Investment Management, which is a
fundamental research driven investment management company that is exclusively
focused on the global health care and bioscience industries. Prior to joining
Oracle Investment Management, he worked at Leerink Swann, the Boston
Consulting Group, and the Food and Drug Administration. Dr. Varma received his
B.A. from the University of California Berkeley, M.D. from the Albert Einstein
College of Medicine, and M.B.A. from the MIT Sloan School of Management.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
visit www.vermillion.com.

Forward-Looking Statement
Certain matters discussed in this press release contain forward-looking
statements that involve significant risks and uncertainties, including
statements regarding Vermillion's plans, objectives, expectations and
intentions. These forward-looking statements are based on Vermillion's current
expectations. The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for such forward-looking statements. In order to comply with the
terms of the safe harbor, Vermillion notes that a variety of factors could
cause actual results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking statements.
Factors that could cause actual results to materially differ include but are
not limited to: (1) uncertainty as to Vermillion's ability to protect and
promote its proprietary technology; (2) Vermillion's lack of a lengthy track
record successfully developing and commercializing diagnostic products; (3)
uncertainty as to whether Vermillion will be able to obtain any required
regulatory approval of its future diagnostic products; (4) uncertainty of the
size of market for its existing diagnostic tests or future diagnostic
products, including the risk that its products will not be competitive with
products offered by other companies, or that users will not be entitled to
receive adequate reimbursement for its products from third party payers such
as private insurance companies and government insurance plans; (5) uncertainty
that Vermillion has sufficient cash resources to fully commercialize its tests
and continue as a going concern; (6) uncertainty whether the trading in
Vermillion's stock will become significantly less liquid; and (7) other
factors that might be described from time to time in Vermillion's filings with
the Securities and Exchange Commission. All information in this press release
is as of the date of this report, and Vermillion expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
such statements to reflect any change in Vermillion's expectations or any
change in events, conditions or circumstances on which any such statement is
based, unless required by law.

This release should be read in conjunction with the consolidated financial
statements and notes thereto included in our most recent reports on Form 10-K
and Form 10-Q. Copies are available through the SEC's Electronic Data
Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com

SOURCE Vermillion, Inc.

Website: http://www.vermillion.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement